John Hennessy, Associate Principal at Payer Sciences, shared Top 10 Posters from ASCO Quality Care Symposium 2025 (ASCOQLTY 2025) on LinkedIn:
“It’s been a minute…but I’m finally getting to my top 10 posters of ASCOQLTY 2025.
We’ve seen a number of new subcutaneous formulations this year…but not everyone is interested. The University of Kansas Cancer Center folks asked why.”
“Day 2 of top 10 posters from ASCOQLTY 2025. Oncology Pathways aren’t just good medicine…they are good for the practice. Off-pathway had 4x PA denials versus on-pathway…and this is the story that suggests that gold carding makes sense.”
“Day 3 of the top 10 posters from ASCOQLTY 2025. (one man’s opinion).
Patient support services may be helpful in solving for patient affordability for a new late-line drug regimen, but can’t solve for existing medical debt. The team at Fred Hutch shows that existing medical debt delinquency affects adherence to oral anti-cancer medicines.”
“Day 4 of 10…top 10 posters of ASCOQLTY 2025.
It’s about the drugs…75% of the cost of care. One of the many posters from American Oncology Network.”
“Day 5 of 10…Top 10 posters from ASCOQLTY 2025. (I know Lalan Wilfong, M.D., has been waiting for this.
Weight-based dosing for pembro…solid safety and efficacy data, with less resource utilization. Innovation isn’t always about the next shining thing; it can be about getting better at what we do every day. Solid work by Thyme Care.”
“Day 6 of 10. ASCOQLTY 2025, top 10 posters.
When payers and providers align on best practices for biomarker testing and streamline the ordering process, everyone wins. Patients get tested. Oncologists get a reduced administrative burden. Patients get affordable testing. Props to Texas Oncology.”
“Day 8…top 10 posters from ASCOQLTY 2025.
It’s not just CCA… minimizing language is across all different cancer trials… ‘no new signals’… ‘tolerable side effects’. This puts burdens both on patients and health care delivery systems.”
“Day 9 of 10. Top 10 posters from ASCOQLTY 2025 (a little late)
I’m a big fan of AccessHope. It’s my first recommendation for self-funded employers looking to address quality and cost for cancer care.
5 years of data on recommendations. I would have liked to see how many of the clinical trial recommendations lead to trial enrollment, especially in the more geographically challenged populations.”
“Day 10 of 10. Top posters from ASCOQLTY 2025.
Shared decision-making is good for patients. Period. That is personalized medicine.”
More posts featuring John Hennessy on OncoDaily.